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Abstract
Background: Disease genes cause or contribute genetically to the development of the most complex diseases.
Drugs are the major approaches to treat the complex disease through interacting with their targets. Thus, drug
targets are critical for treatment efficacy. However, the interrelationship between the disease genes and drug
targets is not clear.
Results: In this study, we comprehensively compared the network properties of disease genes and drug targets for
five major disease categories (cancer, cardiovascular disease, immune system disease, metabolic disease, and
nervous system disease). We first collected disease genes from genome-wide association studies (GWAS) for five
disease categories and collected their corresponding drugs based on drugs’ Anatomical Therapeutic Chemical
(ATC) classification. Then, we obtained the drug targets for these five different disease categories. We found that,
though the intersections between disease genes and drug targets were small, disease genes were significantly
enriched in targets compared to their enrichment in human protein-coding genes. We further compared network
properties of the proteins encoded by disease genes and drug targets in human protein-protein interaction
networks (interactome). The results showed that the drug targets tended to have higher degree, higher
betweenness, and lower clustering coefficient in cancer Furthermore, we observed a clear fraction increase of
disease proteins or drug targets in the near neighborhood compared with the randomized genes.
Conclusions: The study presents the first comprehensive comparison of the disease genes and drug targets in the
context of interactome. The results provide some foundational network characteristics for further designing
computational strategies to predict novel drug targets and drug repurposing.
Background
In the past decade, discovering the genes underlying dis-
ease susceptibility in human (disease genes) has been a
major task in biomedical research area. These disease
genes cause or contribute genetically to the development
of the most complex diseases such as cancer [1], diabetes
[2], and schizophrenia [3]. Completely understanding of
the genetic predisposition of complex diseases is critical
for discovering novel drug targets and developing new
treatment strategies [4,5]. For example, some of these
disease genes have been successfully employed in clinical
application to seek more efficient and less toxic therapies.
In breast cancer, the germline BRCA1/BRCA2 genotyping
is used to determine susceptibility to breast and ovarian
cancer[6-8] and the elevated expression level of circulat-
ing tumor marker HER-2 is used to determine the treat-
ment of the monoclonal antibody Trastuzumab [9,10].
Though the clinical application of these disease genes has
fueled discoveries of disease biomarkers and drug targets,
successful cases are still very limited compared to the
large number of disease genes. Recently, disease genes
have been regarded as a major source for determining
novel drug targets for human disorders [11-13]. However,
how the drug targets influence the disease genes is not
clear. Thus, we hypothesized that investigating their rela-
tionship in the context of networks will provide some
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novel insights for further understanding of the molecular
mechanism underlying treatment, which in turn may
facilitate the identification of novel drug targets and the
development of computational approaches for drug
repurposing and drug combinations.
With the development of large-scale technologies such
as genome-wide association study (GWAS) and next
generation sequencing (NGS), molecular and genetic
studies of human diseases have discovered an impressive
number of associations between genes and various dis-
eases [14,15]. GWAS especially has been used as a
major tool to query common genetic variations across
the entire human genome in an unbiased fashion. It
allowed for the discovery of a number of new gene
regions contributing to multifactorial diseases [16].
More importantly, the National Human Genome
Research Institute (NHGRI) Catalog of Published Gen-
ome-wide Association Studies (GWAS catalog) has a
collection of all published GWAS [17], which provides
comprehensive insights into the functional implication
for human diseases and traits at the systematic level.
Likewise, multiple drug-centered databases such as
DrugBank [18] and PharmGKB [19] provide comprehen-
sive data for systematic analysis. The extensive data
from both areas makes it possible and practical to inves-
tigate the interrelationship between disease genes and
drug targets at the systemic level. Although the data
may be incomplete or error-prone, it nonetheless offers
us an unprecedented opportunity to uncover their con-
nections. Recently, a network-based approach to human
disease (network medicine) has become a major and
powerful tool for identifying new disease genes, unco-
vering the biological significance of disease-associated
mutations, and identifying drug targets and biomarkers
for complex diseases [15,20-23]. In biological networks,
the implications of the topological properties of the
nodes can provide an overview of the organizing princi-
ples that govern both the networks and nodes’ biological
meanings [24-26]. Therefore, our goal here is to under-
stand the interrelationship between disease genes and
drug targets in the context of the human protein-protein
interaction (PPI) networks.
In this study, we determined five different disease cate-
gories based on the disease and traits from the GWAS
data and then collected the disease genes and drug tar-
gets for the common disease. In the context of human
diseases, drug target genes were defined by mapping the
drug targets to their encoding genes, while, in the context
of the PPI network, the nodes mapping to disease genes
were defined as disease proteins. We first compared the
overlap between the disease genes and drug target genes.
Then, by mapping the disease genes and drug target
genes onto the human interactome, we calculated the
three basic topological measurements, i.e., degree,
betweenness, and clustering coefficient. We further
examined the neighborhoods of disease proteins by quan-
tifying the fraction of drug targets that were in an eighth-
degree neighborhood around a disease protein. The same
was done in the neighborhoods of drug targets and the
fraction of disease proteins. This study first systematically
investigated the interrelationship between the disease
genes and drug targets in the context of networks, pro-
viding some foundational network characteristics for
further design of computational strategies for predicting
novel drug targets and drug repurposing.
Materials and methods
Disease genes from GWAS catalog
In this study, the disease genes were defined as the
reported genes provided by the NHGRI Catalog of Pub-
lished GWAS Catalog [27]. The GWAS catalog provides a
quality-controlled, manually-curated, literature-derived
collection of all published GWAS [17]. It collects the pub-
lished information such as PubMed ID, reported genes,
SNP-located genes, SNPs, and SNP-trait association
P-values from the GWAS and has assayed at least 100,000
SNPs, listing those SNP-trait associations with P-values
less than 1.0 × 10-5. We downloaded the data from the
GWAS catalog website https://www.genome.gov/
26525384, November 2013). Additionally, the European
Bioinformatics Institute (EBI) Functional Genomics Pro-
duction Team generated a GWAS diagram browser using
semantic web technologies http://www.ebi.ac.uk/fgpt/
gwas/ for exploring the GWAS [27]. Along with generat-
ing the browser, the researchers have formalized the
GWAS traits by mapping each trait to one or more terms
through the Experimental Factor Ontology (EFO). We
downloaded the EFO mapping file (November 2013),
which includes the relationship between each study trait
to the thirteen parent SNP-associated trait categories.
Among the thirteen trait categories, six were directly
related to one major type of disease, such as cancer, cardi-
ovascular disease, digestive system disease, immune system
disease, metabolic disease, and nervous system disease.
Considering that digestive diseases (gastrointestinal disor-
ders) belong to code A (Alimentary tract and metabolism)
in the drug Anatomical Therapeutic Chemical (ATC) clas-
sification system, we grouped the digestive and metabolic
diseases into the same category. Thus, in this study, there
were five different disease categories: cancer, cardiovascu-
lar disease, immune system disease, metabolic disease, and
nervous system disease. For each disease category, genes
with SNPs having GWAS significant P-values of less than
1.0 × 10-8 were defined as disease genes [28]. Then, we
matched them to the gene IDs and gene symbols from the
latest version of gene annotation downloaded from the
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NCBI human reference genome Entrez Gene [29] to
represent the disease genes.
Drugs and their targets
We downloaded the DrugBank database (version 3.0) as
of October 2013. DrugBank combines comprehensive
drug-related information data including the drug-target
and drug ATC code information [18]. For each drug, we
extracted several fields such as “Name”, “Drug Target”,
and “ATC Codes” data to obtain primary drug targets
and drug ATC annotations. We utilized the DrugBank
drug IDs and drug names to represent the drugs. For
drug targets, we first downloaded the unique UniProtKB
accession numbers (ACs) to represent protein targets
and matched them to gene symbols through two steps.
First, we mapped UniProtKB ACs to Entrez gene IDs by
the ID Mapping tool in the UniProt database [30] and
then mapped gene IDs to gene symbols according to the
latest annotation file used in the disease gene mapping.
Matching between GWAS traits and drug indications
using ATC classification
To match drug indications to GWAS traits, we utilized the
drug Anatomical Therapeutic Chemical (ATC) classifica-
tion http://www.whocc.no/atc_ddd_index/. The classifica-
tion system groups the active drugs into five different
levels based on the organ or system on which they act as
well as their therapeutic and chemical characteristics. Its
first level has fourteen anatomical main groups, of which
each is represented by one letter. For example, N repre-
sents “nervous system.” The second sublevel of the ATC
coding system contains systems-specific therapeutic sub-
groups represented by a two-digit number. For example,
N05 represents “psycholeptics,” a therapeutic subgroup of
the anatomical group N “nervous system.”
To complement the drug ATC annotation from the
DrugBank database, we further utilized ATC classification
annotations for each drug from the Kyoto Encyclopedia of
Genes and Genomes (KEGG) drug database [30]. We
downloaded the drug information file from KEGG FTP
website ftp://ftp.genome.jp/pub/kegg/medicus/ in Novem-
ber 2013 and then extracted the ATC annotation for each
drug. We then merged the ATC annotation from the two
databases by removing redundancies.
We manually searched the ATC codes for five different
disease categories and then matched the drug indications
to disease categories through the following drug ATC
codes. The drugs belonging to the L01 (Antineoplastic
agents) class were defined as treatment of cancer; the
drugs belonging to the L03 (Immunostimulants) and L04
(Immunosuppressants) as the treatment of immune
system diseases; the drugs belonging to the N (Nervous
system) as the treatment of nervous system disease; the
drugs belonging to the C (Cardiovascular system) as the
treatment of cardiovascular system diseases; and the
drugs belonging to the A02 (Drugs for acid related disor-
ders), A03 (Drugs for functional gastrointestinal disor-
ders), A04 (Antiemetics and antinauseants), A05 (Bile
and liver therapy), A06 (Drugs for constipation), A07
(Antidiarrheals, intestinal anti-inflammatory/anti-infec-
tive agents), and A10 (Drugs used in diabetes) as the
treatment of metabolic diseases. For those that mapped
to different categories of diseases, we assigned them to
multiple disease groups.
Protein-protein interaction data and analysis
We downloaded the latest version of the human PPI
data from the Protein Interaction Network Analysis
platform (PINA v2.0) (http://csbi.ltdk.helsinki.fi/pina/,
September 2013) [31]. We retrieved the experimentally
verified PPI data for further analysis and then mapped
the protein identifications to the official gene symbols.
After removing redundancies and self-interactions, we
obtained one human PPI network, which included
101,219 edges connecting 12,978 nodes.
In this study, we calculated the three basic network
topological measures, i.e., degree, betweenness, and clus-
tering coefficient, in order to examine network proper-
ties of ten sets of proteins in the PPI network, as
described in our previous study [25]. In the biological
networks, the degree of a node (connectivity) is the
count of its direct links, which is the most basic network
property., The more links a node has, the more impor-
tant it is in terms of network stability [32]. Second, the
betweenness of a node is defined as the number of
shortest paths between all possible pairs of nodes in the
network that traverse the node. It measures the ways in
which signals can pass through the interaction network
[33]. Finally, the clustering coefficient of a node is the
ratio of the observed number of direct connections
between the node’s immediate network neighbors over
the maximum possible number of such connections. It
measures the density of its neighborhood, which means
weather or not the node’s interactors could form mod-
ules. In biological networks, the components in a mod-
ule often work together to achieve a relatively distinct
function.
To further investigate the interrelationship between
disease proteins and drug targets in the human interac-
tome, we examined their neighborhoods by quantifying
the fraction of drug targets in the disease protein neigh-
borhood or the fraction of disease proteins in the drug
target neighborhood. To do this, we examined the eight-
degree level of the neighborhood for each node. For
example, for a given disease protein A, we collected the
nodes that have direct links with it as its first-degree
neighbors. From its first-degree neighbors, we collected
the nodes having direct links with them and excluded
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the disease proteins as its second-degree neighbors.
From its second-degree neighbors, we collected the
nodes that have direct links with second-degree neigh-
bors and excluded its first-degree neighbors as its third-
degree neighbors. We continued this pattern five more
times, ending on the eighth-degree neighbors. For a
given disease protein at a given degree, we calculated
the fraction of targets in its neighbors as the number of
nodes belonging to targets divided by the number of tar-
gets. For a given target, For a given target at a given
degree, we calculated the fraction of disease proteins in
its neighbors as the number of nodes belonging to dis-
ease proteins divided by the number of disease proteins.
Results and discussion
Disease genes and drug target genes
Using the GWAS association results from the GWAS
catalog, we obtained five sets of disease genes with
SNPs having significant P-values of less than 1.0 × 10-8.
Then, based on the GWAS trait classification from EBI,
we classified the gene sets into five different disease
categories (cancer, cardiovascular disease, immune sys-
tem disease, metabolic disease, and nervous system dis-
ease) for further analyses. Thus, we obtained a total of
1,344 disease genes from 450 GWA studies of five dis-
ease categories (Table 1). The numbers for the five sets
of disease genes ranged from 162 for nervous disease to
601 for metabolic disease. Figure 1A shows their inter-
sections. Among them, the metabolic and immune dis-
ease-associated genes had many common genes (117,
35.67%), which indicated that more than one third of
the immune disease genes were reported to be signifi-
cantly associated with the metabolic disease. This obser-
vation was consistent with the idea that the metabolic
and immune systems have many links on multiple levels
in the biological processes [34].
We extracted drugs and their targets from DrugBank
database. To match drug indications to GWAS trait
classes, we employed the drug ATC classification. We
obtained drugs’ ATC codes from DrugBank and KEGG
databases. Accordingly, we obtained a total of 827 drugs
for five disease categories (Table 1). Among them, 25
drugs belonged to two categories of disease and one
drug belonged to three categories. Thus, we classified a
total of 719 targets into five different disease categories.
The numbers of the five sets of drug target genes ranged
from 70 for immune disease to 273 for nervous disorder.
Figure 1B shows their intersections. Among these over-
lapped drug target genes, one-third of the target genes
for cardiovascular disease also belonged to the target
genes for nervous disease (97, 35.53%) and one-fourth
(25.74%) belonged to the target genes for metabolic dis-
ease. These observations further confirmed that both
the nervous system and metabolic syndrome play impor-
tant roles in the regulation of cardiovascular function
over multiple time scales [35,36].
Table 1 summarizes the disease genes, drugs, drug tar-
get genes, and the ATC codes of drugs for matching
drug indications to GWAS traits. We further examined
the overlaps between the disease genes and drug target
genes for each disease category. The number of genes
common to disease genes and drug target genes was
very small for all five types of diseases (Table 1). How-
ever, when compared to human protein-coding genes,
the disease genes tended to be enriched in the known
drug target genes. Overall, there were 95 common genes
(5.07%) between 1,344 disease genes and 719 drug target
genes. To further evaluate the significance of enrich-
ment for disease gene set in target gene set, we per-
formed the hypergeometric test (PubMed ID: 15980575)
compared with 719 drug target genes of 20,629 human
protein-coding genes. The result indicated that the over-
all disease gene set was enriched in the target gene set,
which was more than expected by chance (Hypergeo-
metric test P-value: 1.6 × 10-11). The observation indi-
cated that the disease genes tend to be druggable, which
is consistent with the previous results that GWAS genes
are significantly more likely to be theoretically druggable
or biopharmable targets than expected by chance [12].
Similarly, we further assess the significance of the
enrichment for disease gene set in target gene set for
each disease categories. Compared to the 791 drug tar-
get genes of 20,629 human protein-coding genes, the
disease gene set was significantly enriched in target
Table 1 Summary of GWA studies, disease genes, SNPs, drugs, and target genes for five disease categories
Disease category GWAS Gene SNP Drug Target Overlapa P-valueb ATC codec
Cancer 147 326 341 115 171 7 0.01 L01
Cardiovascular 52 177 202 230 273 5 0.06 C
Immune 92 328 398 49 70 8 1.3 × 10-5 L03, L04
Metabolic 90 601 561 146 185 13 2.0 × 10-3 A02, A03, A04, A05, A06, A07, A10
Nervous 74 162 178 314 248 3 0.18 N
Total 450 1,344 1,586 827 719 95 1.6 × 10-11
aThe number of common genes between disease genes and drug target genes for each disease category.
bThe P-value was calculated by hypergeometric test on the common genes between disease genes and target genes compared with the human protein-coding
genes for each disease category. cThe detail information for each ATC code was included in the Materials and methods.
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genes in cancer, immune disease, and metabolic disease
(P-values: 0.01, 1.3 × 10-5, and 2.0 × 10-3, respectively)
but not in the cardiovascular and nervous diseases
(P-values: 0.06 and 0.18, respectively) (P-value < 0.05).
This inconsistency might reflect that different disease
categories have different molecular mechanisms, or it
might be due to the study bias of the different disease
categories in biomedical research [37]. More effort
could be made for further improvement of the disease
gene data by including both more general disease data-
bases, such as the Online Mendielian Inheritance in
Man (OMIM) [38] and the Genetic Association Data-
base (GAD) [39], and specific disease gene databases,
such as Catalogue Of Somatic Mutations in Cancer
(COSMIC) [40] for cancer and SchizophreniaGene [41].
Network properties of disease proteins and drug targets
in the human interactome
For each node in the network, the degree, betweenness,
and clustering coefficient, are mostly basic network proper-
ties. In this study, we examined and compared the three
network measurements of five pairs of the disease gene
proteins and drug targets for five disease categories (cancer,
cardiovascular disease, immune disease, metabolic disease,
and nervous disease). Table 2 summarizes the network
properties of the five sets of disease proteins and five sets
of drug targets and Figure 2 shows the comparison of the
distributions of five network properties of disease proteins
and drug targets in the human interactome.
The node’s degree is the most elementary characteristic
of a node, which allows us to compare and characterize
different gene sets. Overall, the average degree of drug
targets tends to be higher than that of the disease pro-
teins in the same disease category. Among the five dis-
ease categories, the average degrees of three drug targets
in three disease categories (cancer, immune, or nervous)
were significantly higher than that of the corresponding
disease proteins (Wilcoxon test, P = 4.2 × 10-7, 1.6 × 10-4,
2.3 × 10-3, respectively). Interestingly, the average degree
of the cancer drug targets was approximately two times
that of the cancer disease proteins. This shows that can-
cer drug targets tend to interact strongly with other pro-
teins and have higher degree in the whole network. This
observation might reflect that the cancer disease genes
and cancer target genes mainly play roles in different bio-
logical processes [12]. To elucidate this difference, we
would need to integrate more data from other cancer-
related gene sources such as cancer gene census [37] and
genes with somatic recurrent mutations from The Cancer
Genome Atlas (TCGA) project [42].
For each node, the betweenness measures the number of
shortest paths between all pairs of nodes in the network
that pass through the node, which may reflect the extent
of signals that might have paths through the node in a bio-
logical network. Similarly, for the five different disease
categories, the overall average betweenness of the drug tar-
gets was higher than of the disease genes. For example, the
average betweenness of the cancer drug targets was signifi-
cantly greater than that of the cancer disease proteins
(Wilcoxon test, P = 7.5 × 10-7). A similar difference could
be seen between the immune drug targets (P = 7.5 × 10-7)
and the immune disease proteins (P = 2.0 × 10-3), while
Figure 1 Comparisons among five sets of disease genes (A) and five sets of drug target genes (B) for five disease categories. The five
disease categories included cancer, cardiovascular disease, immune system disease, metabolic disease, and nervous system disease.
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for cardiovascular, metabolic, nervous diseases, the com-
parison did not reach significance. Finally, a higher cluster-
ing coefficient of a node indicates a higher density of its
network connections. The average clustering coefficient of
the target proteins in cancer, cardiovascular disease, and
immune disease were not significantly lower than the cor-
responding average clustering coefficient in each category
(P = 0.30, 0.14, and 0.33, respectively) but the average
Table 2 Summary of network properties for disease genes and drug target genes in the human interactome
Disease category No. of proteins Degree Betweenness (1.0 × 104) Clustering coefficient
Disease Target Disease Target Disease Target Disease Target
Cancer 270 171 24.59 48.34 2.78 6.40 0.14 0.13
Cardiovascular 145 273 19.43 25.41 2.04 3.56 0.13 0.11
Immune 264 70 20.47 32.41 2.19 5.69 0.16 0.14
Metabolic 487 187 21.13 18.56 2.51 2.91 0.15 0.08
Nervous 125 249 16.68 23.25 1.81 2.73 0.17 0.11
Total 1065 643 20.25 26.12 2.23 3.51 0.15 0.12
Figure 2 Comparison of three network properties of disease proteins and drug targets in the five disease categories.
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clustering coefficient of the target proteins in metabolic
and nervous disease categories were significantly lower
than the corresponding average clustering coefficient in
each category (P = 1.3 × 10-4 and 5.8 × 10-4, respectively).
Overall, we found that disease drug targets had higher
degree, higher betweenness, and lower clustering coeffi-
cients, some of which even reached statistical signifi-
cance in certain disease categories. These observations
not only indicated that drug targets had different net-
work properties compared to disease proteins but also
suggested that drugs perform their actions through their
targets disrupting the disease-related modules. There-
fore, when applying network properties to predict drug
targets and potential drug repurposing, it might be
necessary to perform a comprehensive investigation of
those network properties.
Neighborhood of disease proteins and drug targets in
human interactome
Figure 3A shows the fraction of drug targets in the disease
protein neighborhood while Figure 3B shows the fraction
of disease proteins in the drug target neighborhood. The
results show that, for all disease genes and the drug targets
in all diseases, there was an increased enrichment in the
region of the first-degree, second-degree, and third-degree
when compared with the randomized nodes to the total
disease gene size or the drug target size, which is consis-
tent with the results observed by Yildirm et al. using the
shortest path distance to compare the disease proteins
from the OMIM and drug targets [43].
To further examine if the fraction of disease genes in the
target neighborhoods, or the fraction of targets in the
disease gene neighborhood, is higher than that
of randomized nodes, we performed the one-sided
Wilcoxon tests at first-degree, second-degree, and third-
degree, respectively. Table 3 summarizes the Wilcoxon
test P-values. The results showed that, compared to the
randomized nodes, the fractions of targets in the disease
gene neighborhood or the fractions of disease genes in the
target neighborhood are significantly higher than that in
the randomized node’s neighborhood in the cancer, cardi-
ovascular and immune disorders, respectively (P-value <
0.05). However, in the metabolic and nervous disorders,
we did not observe the significance. These observations
suggest that, different types of disorders have their charac-
teristics, which might be caused by their particular pathol-
ogy. When applying the relationship between the disease
proteins and known drug targets to predict the novel drug
targets in the context of the networks, it is necessary to
extensively investigate the relationship between the disease
genes and drug targets. Even though, our results overall
suggest, in cancer, cardiovascular and immune disorder, it
might be an appropriate option to utilize the disease gene
and target relationship up to third-degree in the context of
networks when applying the network properties for drug
discovering design.
Conclusion
This study is important because of the slowness of drug
discovery and increase of drug discovery cost. The
emerging area of computational network pharmacology
provides complementary approaches for facilitating the
drug development. However, more work is necessary to
identify common patterns of drug targets, disease genes,
Figure 3 Neighborhood of disease proteins (A) and drug targets (B) in five different disease categories.
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and their interrelationship in the context of networks.
The findings in this study could be used to design the
computational methods for drug target identification,
drug repurposing, and drug combination when taking
drug target network as one factor.
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